Targeting protein tyrosine phosphatase non-receptor type 2 with a novel inhibitor for AML therapy
W. Kuang, J. Jiang, X. Wang, D. Wang, M. Ji, Y. Zhu, K. Yuan, J. Ding, W. Wang, M. Song, W. Min, F. Huang, L. Wang, W. Gu, H. Hao, , P. Yang
This study identifies PTPN2 as a therapeutic target in AML, discovers a selective inhibitor K73, and demonstrates its efficacy in reducing AML burden in vitro and in vivo.
bioRxiv · May 7, 2024 · PreprintCancer Biology